• Chinese herb medicine
• mechanism
• natural product
• peripheral nerve injury
• peripheral nerve regeneration

• Drugs, Chinese Herbal/therapeutic use
• Drugs, Chinese Herbal/pharmacology
• Humans
• Peripheral Nerve Injuries/drug therapy
• Animals
• Nerve Regeneration/drug effects
• Medicine, Chinese Traditional

• Angiogenesis
• Diabetes mellitus
• Diabetic foot ulcers
• Diabetic wound
• Timing of treatment

• Intestinal colic
• Lamp irradiation
• Purple gromwell oil gauze
• Radical surgery for colorectal cancer
• Therapeutic effect

• amphibians
• fetal skin
• oral mucosa
• scarless
• skin
• wound healing

• Humans
• Wound Healing/drug effects
• Animals
• Biocompatible Materials/pharmacology
• Biocompatible Materials/chemistry
• Cicatrix
• Skin/pathology

• alternative medicine
• complementary medicine
• glycemic control
• herbal remedies
• mind-body therapies
• patient education
• type 2 diabetes

• diabetic foot
• meta-analysis
• phytotherapy
• plant extracts
• wound healing

• Humans
• Diabetic Foot/drug therapy
• Randomized Controlled Trials as Topic
• Ulcer/drug therapy
• Bandages
• Administration, Oral
• Diabetes Mellitus/drug therapy

• 1475 Abadan University of Medical Sciences, Abadan, Iran

• collagen deposition
• fibroblast proliferation
• inflammatory response
• quercetin
• wound healing

• WL-HBQN-2022012K Future Plan for Traditional Chinese Medicine Development of Science and Technology of Shanghai Municipal Hospital of Traditional Chinese Medicine
• ZY (2021-2023)-0211 The three-year action plan project for Shanghai to further accelerate the inheritance, innovation and Development of Traditional Chinese Medicine
• Shanghai Collaborative Innovation Center of Industrial Transformation of Hospital TCM Preparation
• 20204Y0180 Shanghai Municipal Health Commission Clinical Research Project
• 2021LK083 Shanghai University of Traditional Chinese Medicine budget project
• 22Y11922600 Special medical innovation research project of "scientific and technological innovation action plan" of Shanghai Science and Technology Commission
• 3550 Train outstanding TCM talents in Shanghai University of Traditional Chinese Medicine Project

• Chronic wounds
• Combination therapy
• Commensal microbiome
• Drug carriers
• Immune response
• Traditional herbal medicine
• Wound healing

Globally, approximately one-third of ischemic heart diseases are due to hyperlipidemia, which has been shown to cause various metabolic disorders. This study was aimed to disassemble and analyze hypolipidemic formulae sold by traditional Chinese medicine (TCM) pharmacies. Using commonly used statistical parameters in ethnopharmacology, we identified the core drug combination of the hypolipidemic formulae, thereby exploring the strategy by which the Taiwanese people select hypolipidemic drugs. Most important of all, we preserved the inherited knowledge of TCM. We visited 116 TCM pharmacies in Taiwan and collected 91 TCM formulae. The formulae were mainly disassembled by macroscopical identification, and the medicinal materials with a relative frequency of citation (RFC) >0.2 were defined as commonly used medicinal materials. Subsequently, we sorted the information of medicinal materials recorded in the Pharmacopeia, searched for modern pharmacological research on commonly used medicinal materials using PubMed database, and visualized data based on the statistical results. Finally, the core hypolipidemic medicinal materials used in folk medicine were obtained. Of the 91 TCM formulae collected in this study, 80 traditional Chinese medicinal materials were used, belonging to 43 families, predominantly Lamiaceae. Roots were the most commonly used part as a medicinal material. There were 17 commonly used medicinal materials. Based on medicinal records in Pharmacopeia, most flavors and properties were warm and pungent, the majority traditional effects were “tonifying and replenishing” and “blood-regulating.” Besides, the targeted diseases searching from modern pharmacological studies were diabetes mellitus and dyslipidemia. The core medicinal materials consisted of Astragalus mongholicus Bunge and Crataegus pinnatifida Bunge, and the core formulae were Bu-Yang-Huan-Wu-Tang and Xie-Fu-Zhu-Yu-Tang. In addition, 7 groups of folk misused medicinal materials were found. Although these TCMs have been used for a long period of time, their hypolipidemic mechanisms remain unclear, and further studies are needed to validate their safety and efficacy.

• Chinese herbs
• Diabetic ulcers
• Gene set enrichment analysis
• Ingenuity pathway analysis
• Sheng-ji Hua-yu

• Animals
• Humans
• Mice
• Diabetes Complications
• Diabetes Mellitus, Experimental
• Drugs, Chinese Herbal/therapeutic use
• RNA, Messenger/genetics
• RNA, Messenger/metabolism
• Skin Ulcer/drug therapy
• Skin Ulcer/etiology
• Wound Healing/drug effects

• Fish gelatin
• biomedical applications
• drug delivery
• food formulation
• tissue engineering
• wound healing

Common chronic wounds include diabetic ulcers, venous ulcers, and pressure ulcers. The traditional Chinese medicine Huiyang Shengji decoction (HYSJD) has been shown to promote the healing of diabetic chronic wounds, however, its pharmacological mechanism is still unclear.

This study aimed to determine the mechanism of HYSJD in promoting the healing of diabetic chronic skin ulcers.

Ultra-performance liquid chromatography was combined with tandem mass spectrometry (UPLC-MS/MS) to analyze the main components of HYSJD and the absorbed components in mouse serum at 30 min after oral administration of HYSJD. db/db mouse models for chronic skin ulcers were constructed by full-thickness skin resection. Wound tissues at day 7 post wound formation were used to perform microarray analysis of growth factors and chemokine expression. GO and KEGG enrichment analysis was performed on differentially expressed proteins. ELISA assays were used to measure differential expressed cytokines in the serum and Western blot analysis was used to determine the expression levels of related pathway proteins in the skin wounds.

UPLC-MS/MS analysis showed that the main chemical components of HYSJD were flavonoids, terpenes, alkaloids, phenylpropanoids, and carbohydrates. At 30 min after oral administration of HYSJD, five absorbed components were detected in the serum, these included formononetin, calycosin, hypaconitine, calycosin-7-glucoside, and sinapic acid. HYSJD was found to increase the wound healing rate in chronic skin ulcers in db/db mice at days 3, 7, and 14 post wound formation, and promote the proliferation of epidermal cells. Two proteins that were differentially expressed between the different groups, i.e., IGF-1 and EGFR, were further validated. Serum ELISA assays showed that serum EGFR in the HYSJD treatment group was significantly increased. KEGG pathway analysis suggested that the PI3K/AKT pathway involved in HYSJD promoting the proliferation of epidermal cells in chronic wounds in db/db mice. Experimental verification showed that HYSJD activated the PI3K/AKT signaling pathway in mouse wound skin.

HYSJD promotes the proliferation of epidermal cells in chronic diabetic wounds by increasing EGFR expression in the wounds and activating the PI3K/AKT signaling pathway. Our study provides an experimental basis for the pharmacological mechanism of HYSJD.

The online version contains supplementary material available at 10.1186/s13020-021-00497-0.

• Huiyang Shengji decoction (HYSJD)
• Traditional Chinese medicine
• Wound healing

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For the management of OIPN, accurate diagnosis and understanding of significant risk factors including genetic vulnerability are essential to improve knowledge regarding the prevalence and incidence of OIPN as well as enhance strategies for the prevention and treatment of OIPN. The molecular mechanisms underlying OIPN are complex, with multi-targets and various cells causing neuropathy. Furthermore, mechanisms of OIPN can reinforce each other, and combination therapies may be required for effective management. However, despite intense investigation in preclinical and clinical studies, no preventive therapies have shown significant clinical efficacy, and the established treatment for painful OIPN is limited. Duloxetine is the only agent currently recommended by the American Society of Clinical Oncology. The present article summarizes the most recent advances in the field of studies on OIPN, the overview of the clinical syndrome, molecular basis, therapy development, and outlook of future drug candidates. Importantly, closer links between clinical pain management teams and oncology will advance the effectiveness of OIPN treatment, and the continued close collaboration between preclinical and clinical research will facilitate the development of novel prevention and treatments for OIPN.

• Clinical syndrome
• Drug development
• Gut microbiota
• Molecular basis
• Oxaliplatin-induced peripheral neuropathy
• Oxidative stress

• Inflammation
• NLRP3 inflammasome
• eye diseases
• natural products.
• treatment

• Cell types
• Hemostasis
• Inflammation
• Phytomedicine
• Remodeling
• Wound healing

• Chinese herbal
• CircRNA-miRNA-mRNA network
• Diabetic ulcers
• Transcriptional profiling
• Wound healing

• Animals
• Biomarkers/metabolism
• Diabetes Mellitus, Experimental/drug therapy
• Diabetes Mellitus, Experimental/genetics
• Diabetes Mellitus, Experimental/metabolism
• Drugs, Chinese Herbal/pharmacology
• Drugs, Chinese Herbal/therapeutic use
• Gene Expression Profiling/methods
• Gene Regulatory Networks/drug effects
• Gene Regulatory Networks/genetics
• Male
• Mice
• Mice, Inbred C57BL
• MicroRNAs/genetics
• RNA, Circular/genetics
• RNA, Messenger/genetics
• Treatment Outcome
• Wound Healing/drug effects
• Wound Healing/genetics

• Alkanna tinctoria
• Burn
• Calendula tripterocarpa
• Matricaria aurea
• Myrrh

• Kigelia africana
• diabetes mellitus
• GC-TOF-MS
• antioxidant enzymes
• avidin-biotin immunoperoxidase

• Bioseparation optimization
• Diffusion
• Macroporous resin
• Phelligridin LA
• Response surface methodology
• Thermodynamics and kinetics

• Adsorption
• Antioxidants/chemistry
• Basidiomycota/metabolism
• Biotechnology/methods
• Diffusion
• Entropy
• Fermentation
• Hydrogen-Ion Concentration
• Industrial Microbiology/methods
• Kinetics
• Porosity
• Resins, Synthetic/chemistry
• Temperature
• Thermodynamics
• Time Factors

Oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe and potentially permanent side effect of cancer treatment affecting the majority of oxaliplatin-treated patients, mostly with the onset of acute symptoms, but also with the establishment of a chronic sensory loss that is supposed to be due to dorsal root ganglia neuron damage. The pathogenesis of acute as well as chronic OIPN is still not completely known, and this is a limitation in the identification of effective strategies to prevent or limit their occurrence. Despite intense investigation at the preclinical and clinical levels, no treatment can be suggested for the prevention of OIPN, and only limited evidence for the efficacy of duloxetine in the treatment setting has been provided. In this review, ongoing neuroprotection clinical trials in oxaliplatin-treated patients will be analyzed with particular attention paid to the hypothesis leading to the study, to the trial strengths and weaknesses, and to the outcome measures proposed to test the efficacy of the therapeutic approach. It can be concluded that (1) prevention and treatment of OIPN still remains an important and unmet clinical need, (2) further, high-quality research is mandatory in order to achieve reliable and effective results, and (3) dose and schedule modification of OHP-based chemotherapy is currently the most effective approach to limit the severity of OIPN.

• acute
• chronic
• neuropathy
• neurotoxicity
• oxaliplatin
• pain
• prevention
• treatment

• Diabetes
• antioxidants
• diabetic neuropathy
• microbiome
• nutraceuticals
• plants
• prebiotics
• probiotics.

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

• diabetes mellitus
• glucose-lowering agents
• metabolic syndrome
• phytotherapy
• sugar-lowering oils